A phase I trial of solid-dose formulation of BHV-5000 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 14 Aug 2018
At a glance
- Drugs BHV 5000 (Primary)
- Indications Neurological disorders; Rett syndrome
- Focus Pharmacokinetics
- 14 Aug 2018 Accordign to a Biohaven Pharmaceuticals media release, company anticipates completion of this trial in the second half of 2018.
- 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the first patient has been dosed with BHV-5000.
- 18 Jan 2018 According to a Biohaven Pharmaceuticals media release, the US FDA has notified the Company that it may proceed with its clinical investigation of BHV-5000